Abstract
Chronic active Epstein Barr Virus (CAEBV) is a rare and severe condition occurring in previously healthy individuals associated with persistent EBV viraemia, fever, lymphadenopathy and hepatosplenomegaly.
Specific deletions in the EBV genome have been found in CAEBV and certain lymphomas. However, it is unclear how stable these deletions are, whether they are present in different sites and how they evolve in response to treatment. We sequenced fifteen longitudinal blood samples from three CAEBV patients, comparing the results with 13 saliva samples from CAEBV patients and sequences from benign (both primary infection and reactivation) and malignant EBV-related conditions. We observed large EBV deletions in blood, some of which are predicted to disrupt viral replication, but not saliva from patients with CAEBV. Deletions were stable over time but were lost following successful peripheral blood stem cell transplants (PBSCT) or in one case, treatment with rituximab. Our results are consistent with the likelihood that certain deletions occurring in virus from patients with CAEBV are associated with the evolution and persistence of haematological clones. We propose that the loss of EBV deletions following successful treatment should be investigated as a potential biomarker to aid management of CAEBV.
Key points
Unique EBV deletions are found in European CAEBV patients.
Loss of deletions occurs following effective treatment and may prove useful in the management of disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CV was supported by the Wellcome Trust Collaborative Award [204870/Z/16/Z]; SM by a WT Henry Wellcome fellowship [206478/Z/17/Z]. PJF was supported by MRC grant MR/S022597/1 and by NIHR Imperial BRC. JB is supported by the NIHR UCL/UCLH BRC. This work was supported by the intramural research program of the National of Allergy and Infectious Diseases.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were supplied to the study in an anonymized form. Approval for use of anonymized residual diagnostic specimens was obtained through the University College London/University College London Hospitals (UCL/UCLH) Pathogen Biobank National Research Ethics Service Committee London Fulham (Research Ethics Committee reference: 12/LO/1089).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequence reads for CAEBV and PID patients have been deposited in NCBI Sequence Read Archive under BioProject ID PRJEB41945. All accession numbers for the rest of the dataset are available in Table S1.